全文获取类型
收费全文 | 6522篇 |
免费 | 365篇 |
国内免费 | 271篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 97篇 |
妇产科学 | 188篇 |
基础医学 | 584篇 |
口腔科学 | 229篇 |
临床医学 | 698篇 |
内科学 | 1747篇 |
皮肤病学 | 83篇 |
神经病学 | 513篇 |
特种医学 | 76篇 |
外国民族医学 | 11篇 |
外科学 | 704篇 |
综合类 | 615篇 |
现状与发展 | 5篇 |
预防医学 | 529篇 |
眼科学 | 79篇 |
药学 | 431篇 |
3篇 | |
中国医学 | 141篇 |
肿瘤学 | 402篇 |
出版年
2024年 | 45篇 |
2023年 | 420篇 |
2022年 | 317篇 |
2021年 | 1295篇 |
2020年 | 716篇 |
2019年 | 431篇 |
2018年 | 311篇 |
2017年 | 300篇 |
2016年 | 265篇 |
2015年 | 287篇 |
2014年 | 492篇 |
2013年 | 525篇 |
2012年 | 206篇 |
2011年 | 246篇 |
2010年 | 164篇 |
2009年 | 163篇 |
2008年 | 160篇 |
2007年 | 129篇 |
2006年 | 104篇 |
2005年 | 91篇 |
2004年 | 85篇 |
2003年 | 63篇 |
2002年 | 63篇 |
2001年 | 59篇 |
2000年 | 32篇 |
1999年 | 29篇 |
1998年 | 34篇 |
1997年 | 38篇 |
1996年 | 16篇 |
1995年 | 19篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 3篇 |
排序方式: 共有7158条查询结果,搜索用时 15 毫秒
61.
目的采用Meta分析对比微波消融(MWA)与肝切除术(LR)治疗结直肠癌肝转移(CRCLM)的效果和安全性。方法检索PubMed、Embase、Cochrane Library、中国生物医学文献数据库、万方、中国知网、维普数据库关于MWA与LR治疗CRCLM的文献,检索时间自建库至2020年8月31日。依据纳入及排除标准筛选文献,以Review Manager 5.3和Stata 14软件进行Meta分析。结果最终纳入13篇文献、共1 534例CRCLM患者,MWA组685例,LR组849例。经异质性检验,1年总体生存率(OS)(I~2=0%,P=0.72)、3年OS(I~2=0%,P=0.86)、5年OS(I~2=0%,P=0.90)均无明显异质性,采用固定效应模型进行分析,结果显示MWA组与LR组间1年OS[HR=0.99,95%CI(0.95,1.02),P=0.44]、3年OS[HR=1.02,95%CI(0.93,1.11),P=0.74]差异均无统计学意义,LR组5年OS高于MWA组[HR=0.82,95%CI(0.69,0.97),P=0.02]。异质性检验示并发症无明显异质性(I~2=0%,P=0.78),以固定效应模型进行分析,结果显示MWA组并发症发生率低于LR组[RR=0.35,95%CI(0.23,0.52),P0.000 01)]。结论 MWA治疗CRCLM早、中期疗效(1、3年OS)与LR相当,远期疗效(5年OS)不及LR,但安全性更高。 相似文献
62.
目的系统评价微波消融(MWA)治疗继发性甲状旁腺功能亢进症(SHPT)的有效性和安全性。方法检索PubMed、Cochrane Library、Embase、中国知网和万方医学网自建库至2020年12月31日发表的MWA治疗SHPT相关文献。采用Stata 15.0软件分析MWA治疗SHPT的有效性和安全性。结果依据纳入及排除标准,最终纳入9篇文献、共249例SHPT患者。与消融前相比,MWA后1天[加权均数差(WMD)=1 142.04,95%CI(783.03, 1 501.06),P0.001]、1周[WMD=859.85,95%CI(758.97,960.74),P0.001]、1个月[WMD=800.29,95%CI(687.12,913.47),P0.001]和6个月[WMD=857.09,95%CI(746.07,968.11),P0.001]的甲状旁腺激素(PTH)水平均显著降低;MWA后1天[WMD=0.39,95%CI(0.33,0.45),P0.001;WMD=0.29,95%CI(0.16,0.41),P0.001]和1周[WMD=0.23,95%CI(0.02,0.43),P0.05;WMD=0.31,95%CI(0.02,0.61),P0.05]钙和磷水平均下降。MWA后神经损伤发生率为1.20%[效应量(ES)=0.02,95%CI(-0.00,0.05),P0.05],低钙血症发生率为21.69%[ES=0.60,95%CI(0.39,0.81),P0.001],声音嘶哑发生率为5.62%[ES=0.06,95%CI(0.03,0.09),P0.001],血肿发生率为1.61%[ES=0.03,95%CI(-0.01,0.06),P=0.095]。结论 MWA治疗SHPT有效且安全。 相似文献
63.
目的采用Meta分析评价超声引导下热消融治疗继发性甲状旁腺功能亢进症(SHPT)的有效性及安全性。方法检索PubMed、EMbase、Cochrane Library、中国知网、维普数据库及万方医学网中热消融治疗SHPT相关文献,检索时间自建库至2020年8月。依据纳入及排除标准筛选文献。采用ReveMan 5.3软件对消融前后血清全段甲状旁腺素(iPTH)、钙、磷水平及并发症行Meta分析。结果共纳入19篇文献、634例SHPT患者。热消融术后1天、1周、1个月及6个月,血清iPTH水平、钙及磷水平均较术前下降(P均0.01)。术后声音嘶哑发生率14.08%[OR=6.99,95%CI(3.00,16.26)],低钙血症发生率34.62%[OR=38.59,95%CI(16.64,89.47)]。结论超声引导下热消融治疗SHPT安全有效。 相似文献
64.
Thainá Gattermann Pereira RD MS Júlia Lima RD Flávia Moraes Silva RD PhD 《JPEN. Journal of parenteral and enteral nutrition》2022,46(5):977-996
Impaired nutrition status is recognized as a risk factor for worse clinical outcomes in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate how undernutrition is diagnosed, its prevalence, and whether there is an association between this condition and clinical outcomes in patients with COPD. The search for this systematic review of observational studies (PROSPERO: CRD42020191888) was performed in the PubMed, Embase, and Scopus databases, with no date or language restrictions. The studies had to report data on the diagnosis of undernutrition and its association with mortality, exacerbation, length of hospital stay, or quality of life in adult patients with COPD. A meta-analysis with a random-effects model was performed to combine data. Forty-nine studies were included (20 of them classified as having a low risk of bias), and the most common diagnostic method of undernutrition was body mass index (BMI) (n = 36). The pooled prevalence of undernutrition was equal to 20% (95% CI, 0.15–0.25; I² = 100%), and it was associated with mortality (risk ratio = 1.97; 95% CI, 1.55–2.50; I² = 98%), exacerbation (risk ratio = 1.73; 95% CI, 1.03–2.91; I² = 96%), and poorer quality of life (mean difference = 8.25; 95% CI, 5.40–11.10; I² = 79%). For all outcomes, the certainty of evidence was very low. In conclusion, undernutrition is prevalent and is associated with poorer outcomes in patients with COPD. However, undernutrition is mainly diagnosed by BMI, which underreports its prevalence, and the certainty of the evidence is very low. 相似文献
65.
Yifeng Ren Mengling Wei Hong Liu Yao Wang Hairuo Chen Zhuohong Li Wei Shi Fengming You 《International wound journal》2021,18(1):32-48
To further identify the real efficacy and safety of dexmedetomidine as an adjuvant to local wound infiltration anaesthesia, we conducted this meta-analysis. The systematic search strategy was performed using PubMed, Embase, Cochrane Library, and Chinese databases. As a result, a total of 23 RCTs (1445 patients) were included. Patients receiving dexmedetomidine combined with local anaesthetics had a lower rescue analgesia rate [risk ratio (RR): 0.48; 95% confidence interval (CI): 0.36-0.65] and lower rescue analgesic consumption [weighted mean difference (WMD): −10.80 mg; 95%CI: −13.28 to −8.31 mg] than patients receiving local anaesthetics alone. The dexmedetomidine-related adverse reactions included bradycardia (RR: 1.33; 95%CI: 0.32-5.56) and hypotension (RR: 3.00; 95%CI: 0.49-18.42). In addition, the time to first analgesic request (WMD: 296.16 minutes; 95%CI: 165.69 minutes ~ 426.63 minutes), incidence of postoperative nausea and vomiting (PONV) and pain scores at 4 hours postoperatively were also significantly lower in patients receiving dexmedetomidine combined with local anaesthetics. This meta-analysis demonstrated that the use of dexmedetomidine as an adjuvant to wound infiltration is effective for reducing the rescue analgesia rate, rescue analgesic consumption and PONV. In addition, limited evidence shows that dexmedetomidine can prolong postoperative analgesia for approximately 5 hours. Further investigations on dexmedetomidine-related adverse reactions and the dose–response effect of dexmedetomidine in wound infiltration are warranted. 相似文献
66.
Diagnostic accuracy of Raman spectroscopy for prostate cancer: a systematic review and meta-analysis
Jae Joon Park Do Kyung Kim Soomin Lee Yoonseo Choi Yon Hee Kim Joon-Ho Lee Ki Hyun Kim Jae Heon Kim 《Translational andrology and urology》2021,10(2):574
BackgroundAlthough various studies have been conducted to demonstrate the possibility of Raman spectroscopy (RS) as a diagnostic tool for prostate cancer (PC), it is difficult to use it in the real clinical area because of imitations in various research processes. Therefore, we did a systematic review and meta-analysis about the accuracy in diagnostic use of RS for PC.MethodsA literature search was done using PubMed, Embase, and Cochrane library databases in March 2019 to analyze the accuracy of RS for diagnosis of PC. The accuracy of RS for diagnosis of PC was evaluated by means of pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC).ResultsFive studies were included for qualitative analysis by screening the remaining articles according to the inclusion and exclusion criteria by means of a systematic review. The pooled sensitivity and specificity of RS were 0.89 (95% CI: 0.87–0.91) and 0.91 (95% CI: 0.89–0.93), respectively. The overall PLR and NLR were 9.12 (95% CI: 4.15–20.08) and 0.14 (95% CI: 0.07–0.29), respectively. The DOR of RS demonstrated high accuracy (73.32; 95% CI: 18.43–291.73). The area under the curves (AUCs) of SROC curves was 0.93.ConclusionsRS is an optical diagnostic method with high potential for diagnosis and grading of PC and has advantages of real-time and convenient use. In order to consider real-time use of RS in an actual clinical setting, more studies for standardization and generalization of RS performance and analytical method must be conducted. 相似文献
67.
68.
Fang Liu Deming Li Xinjing Wang Yuan Cui 《International journal of food sciences and nutrition》2021,72(1):14-25
AbstractWhether polyphenols could ameliorate inflammatory bowel disease (IBD) is still conflicting. To explore the efficacy of polyphenols as an adjuvant therapy for IBD, we conducted this systematic review and meta-analysis. Literature search was performed using PubMed, Web of Science, Scopus and Cochrane databases. Finally, 12 randomized controlled trials (RCTs) were included. In contrast to control group, curcumin treatment significantly improved clinical remission in intention-to-treat (ITT) (OR = 3.36, 95% CI: 1.09–10.37) and per-protocol (PP) analysis (OR = 5.13, 95% CI: 1.84–14.27). Meanwhile, curcumin could significantly ameliorate endoscopic remission (OR = 5.69, 95% CI: 1.28–25.27) and clinical response (OR = 4.69, 95% CI: 1.03–21.47) in PP analysis. Heterogeneity was present across the studies. In conclusions, polyphenols might be an effective adjuvant treatment for ameliorating IBD. Considering the relatively few studies included in our present study, further clinical trials are required to verify the effects of polyphenols on IBD. 相似文献
69.
Objective: To evaluate the effectiveness and safety of Chinese medicine(CM) for Idiopathic pulmonary fibrosis(IPF) patients. Methods: To screened relevant articles, Pub Med, Cochrane Library, Excerpta Medica Datase(EMBASE), China National Knowledge Infrastructure(CNKI), Chinese VIP Information(VIP), Wanfang Database and Chinese Biomedical Database(CBM) were searched in English or Chinese until December 2015 for randomized controlled trials, which compared CM treatment(CM group) with Western medicine or placebo(control group) on IPF. The outcome measures included acute exacerbation, pulmonary function, the St George's respiratory questionnaire(SGRQ) scores, 6-minute walk test(6 MWT) distance, adverse events and mortality. Results: This meta-analysis included 25 randomized controlled trials involving 1,471 patients. Compared with the control group, CM group was superiori in reducing the risk of exacerbation [relative risk(RR)=0.40, 95% CI 0.22 to 0.72, P0.05], improving in forced expiratory volume in one second(FEV1) [standard mean difference(SMD)=0.62, 95% CI 0.40 to 0.84, P0.01] and diffusion capacity for carbon monoxide(DLCO, SMD=0.40, 95% CI 0.22 to 0.58, P0.01), but there was no significant difference in vital capacity(VC, SMD=0.10, 95% CI –0.12 to 0.31, P0.05). This meta-analysis also revealed that CM therapy significantly decreased the SGRQ score(SMD=–0.60, 95% CI –1.14 to –0.05, P0.05) and improved 6 MWT distance(SMD=0.59, 95% CI 0.34 to 0.84, P0.01), compared with the control group. Meanwhile, CM therapy was associated with a low incidence of adverse effects(RR=0.19, 95% CI 0.08 to 0.43, P0.01). However, there was no significant difference in mortality(RR=0.24, 95% CI 0.05 to 1.10, P0.05) between CM and control groups. Conclusions: The pooled outcomes suggest that CM treatment appears benefit in reducing the risk of exacerbation, improving lung function and decreasing the incidence of adverse effects and enhancing the quality of life. However, the outcomes were limited because of the low quality of the included studies. More rigorous clinic trials need to be carried out to provide sufficient and accurate evidence in the future. 相似文献
70.